• Immuneering highlighted Phase 2a results already presented at the 2026 ASCO meeting for atebimetinib with chemotherapy in first-line metastatic pancreatic cancer.
• Patients lived longer than historical outcomes on standard chemotherapy, with responses consistent across cohorts despite different follow-up durations.
• The regimen showed favorable tolerability, with severe treatment-related side effects largely tied to chemotherapy rather than atebimetinib.
• A global Phase 3 MAPKeeper 301 trial is recruiting, with first patient dosing expected in mid-2026 to confirm the survival benefit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.